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3Abstract         
Proteomic analyses facilitate the interpretation of molecular biomarker probes which are very 
helpful in diagnosing schizophrenia. In the current study, we attempt to test whether potential 
differences in plasma protein expressions in schizophrenia (SZ) and bipolar disorder (BD) are 
associated with cognitive deficits and their underlying brain structures.  
 42 plasma proteins of 29 SZ patients, 25 BD patients and 93 non-clinical controls were 
quantified and analysed using multiple reaction monitoring (MRM) based triple quadrupole 
mass spectrometry approach. We also computed group comparisons of protein expressions 
between patients and controls, and between SZ and BD patients, as well. Potential associations 
of protein levels with cognitive functioning (psychomotor speed, executive functioning, 
crystallized intelligence) as well as underlying brain volume in the hippocampus were explored, 
using bivariate correlation analyses.  
 The main finding of this study was that apolipoprotein (ApoC) expression differed 
between patients and controls; and that these alterations in both disease groups were putatively 
related to cognitive impairments as well as to hippocampus volumes. However, none of the 
protein level differences were related to clinical symptom severity. 
 In summary, altered apolipoprotein expression in BD and SZ was linked to cognitive 
decline and underlying morphological changes in both disorders. Our results suggest that the 
detection of molecular patterns in association with cognitive performance and its underlying 
brain morphology is of great importance for understanding of the pathological mechanisms of 
SZ and BD, as well as for supporting the diagnosis and treatment of both disorders. 
41. Introduction 
 Diagnosis of schizophrenia (SZ) or bipolar disorder (BD) is normally based on clinical 
interviews of patients by psychiatrists. However, conventional symptom-based descriptive 
models of bipolar disorder (BD) and schizophrenia (SZ) have recently been complemented by 
a neurobiological approach. According to this biological approach not only do both disorders 
share some clinical features or cognitive impairments, but they also share biological 
mechanisms underlying the clinical and cognitive features. Biological mechanisms of interest 
are assessed by functional (fMRI) and structural neuroimaging (sMRI) data, or protein 
expressions (proteomics). In general, previous proteomic studies in mental disorders yielded 
changes in metabolic and immunological pathophysiological pathways, partly independently of 
treatment or illness status (Schwarz et al., 2010; Schwarz et al., 2012). Moreover, mass 
spectrometry-based proteomics have identified proteins which may serve as biomarker 
candidates to prognosis, diagnosis, and medication monitoring in peripheral tissue (Nascimento 
& Martins-de-Souza, 2015). 
 However, whether changes in the levels of serum proteins may be directly correlated 
with cognitive or clinical features of psychiatric disorders has rarely been investigated. A major 
purpose of the study is to assess whether protein expressions reflect psychiatric illnesses such 
as BD or SZ. A further aim is to link potential pathophysiological abnormalities of BD and SZ 
with cognitive impairments and their underlying brain structure. Apart from clinical features, 
schizophrenia (SZ) and bipolar disorder (BD) share common alterations in cognitive domains, 
e.g., episodic or working memory (Mann-Wrobel, Carreno, & Dickinson, 2013; Schaefer, 
Giangrande, Weinberger, & Dickinson, 2013). These observations challenge previous 
dichotomous approaches of psychosis (Kraepelin, 1919) and indicate the need for searching 
biological (e.g., neuroimaging, molecular) markers underlying shared symptoms of both 
disorders. 
5 Specifically, Apolipoprotein (Apo) levels has been identified as risk factor for several 
neuropsychiatric diseases (Elliott, Weickert, & Garner, 2010), e.g. for Alzheimer’s disease. 
Additionally, previous evidence supports the hypothesis that changes in Apo concentrations 
may be involved in the psychopathology of SZ (Lee, Kim, & Song, 2013; La et al., 2007; Wu 
et al., 2013; (Dassati, Waldner, & Schweigreiter, 2014; Dean, Digney, Sundram, Thomas, & 
Scarr, 2008; Takahashi et al., 2008) (Dean et al., 2008; Digney, Keriakous, Scarr, Thomas, & 
Dean, 2005; Martins-De-Souza et al., 2010; Sasaki, Funakoshi, & Arakawa, 1985) and BD 
(Dassati et al., 2014). In a recent review of Martins-de-Souza and colleagues, they compared 
proteomics in serum of 55 first-onset drug-naïve SZ patients and 33 controls and observed, 
amongst others, the apolipoproteins A1, A2, A4, C1 and D had been differentially expressed. 
According to the authors, this finding supports the idea that there is, in fact, a phospholipid 
dysfunction in SZ (Martins-de-Souza, Guest, Rahmoune, & Bahn, 2012).  
 Furthermore, it has been proposed that altered Apo levels might play a putative 
contributory role in decreased cognitive performance (Dassati et al., 2014; Elliott et al., 2010; 
Huang & Mahley, 2014; La et al., 2007). This assumption could be  validated for dementia 
(Kim et al., 2014). However, this link between cognitive impairments and Apo levels has not 
been done for SZ or BD, so far. A study by Verbrugghe and colleagues conducted and replicated 
a genetic association analysis between disease outcome and cognitive performance in SZ 
(Verbrugghe et al., 2012). They reported that ApoE, ApoER2, very-low-density-lipoprotein 
receptor (VLDLR) and disabled-1 (DAB1) single nucleotide polymorphisms (SNPs) were 
significantly associated with disease outcome, pre-morbid intelligence and verbal memory. 
Thus, the authors concluded that neurodevelopmental/synaptic plasticity genes are involved in 
cognitive deficits in SZ. Nonetheless, to our knowledge, a potential overlap between protein 
concentrations and clinical or cognitive symptoms in BD and SZ has not been systematically 
6investigated, yet. Moreover, alterations in cortical and subcortical regions (i.e., basal ganglia, 
thalamus, cingulate, insula, hippocampus) have been observed (see for review (Ellison-Wright 
& Bullmore, 2010; Gupta et al., 2015; Shenton, Dickey, Frumin, & McCarley, 2001)) 
supporting the idea of shared the neurobiological underpinnings of cognitive impairments in 
both disorders (Ehrlich et al., 2011; Gutierrez-Galve et al., 2011; Hartberg et al., 2010; Hartberg
et al., 2011; Knöchel et al., 2016; Knochel et al., 2014; Oertel-Knöchel et al., 2012).  
 The main purpose of this explorative study is to identify protein levels reflecting the 
pathomechanisms of BD or SZ in a trans-diagnostic approach in contrast to healthy controls. 
Another aim is to explore whether changes in levels of proteins are disorder specific or rather 
reflecting some other phenotype within the patients. It is hypothesised that SZ and BD are the 
result of partly similar underlying biological factors which could explain the aforementioned 
clinical similarities. Finally, it is examine whether protein levels are associated with 
neurocognitive changes and brain structures related to neurocognitive deficits in BD and SZ.  
2. Methods
2.1 Participants
We assessed 29 SZ patients [mean age (Mage) = 37.16 years and standard deviation (SD) 
= 10.96 years] and 25 euthymic BD type I patients (Mage = 37.79 and SD = 10.40 years) without 
any comorbid axis I or II disorders (including drug abuse) according to the DSM-IV criteria 
(APA, 1994). All patients were outpatients of the Department of Psychiatry, Psychosomatic 
Medicine and Psychotherapy, Goethe-University, Frankfurt, Germany. 93 non-clinical 
participants (CON; Mage = 33.59 and SD = 11.18 years) were also included, using sample search 
matched criteria. The selection of the controls was done by searching for matching pairs with 
the SZ and BD patient groups regarding age, gender and education status. Exclusion criteria for 
7all participants were current drug abuse or any acute infection. Potential group differences in 
age, gender and years of education were tested for, which revealed no differences across 
controls, BD or SZ patients in these variables (all p-values > 0.05) (see Table 1 for further 
details). The body mass index (BMI; kg/m2) based on weight and height was calculated for all 
participants. Furthermore, in order to confirm diagnosis and rule out (comorbid) psychological 
and personality disorders in SZ or BD patients, and ruling out any past or present mental illness 
in the control group, the Structured Clinical Interview for DSM-IV (SCID-I and SCID-II; 
German version (Wittchen, Zaudig, & Fydrich, 1997)) was conducted with all participants. 
Only those controls not reporting any mental illness in the past or present and without any first-
degree relatives with any mental disease were included into the study. Participants were 
provided with a description of the study and gave written informed consent before participating. 
Experimental procedures were approved by the ethical board of the medical department of the 
Goethe-University, Frankfurt/Main, Germany.  
--------------------------------------------Insert Table 1 about here--------------------------------------- 
2.2 Data acquisition & preprocessing 
Blood sample collection and plasma digestion 
Venous blood (10 ml) of all participants was collected in the morning (8am) to avoid 
circadian interference in biomarker measurements and aliquoted into two 9.0 ml serum tubes 
(Sarstedt, Numbrecht, Germany). All participants did not eat, drink, or smoke after 10 pm the 
night before blood sampling until the collection was done. This was ensured using an in-house 
questionnaire. Furthermore, all participants received detailed information prior to the blood 
draw.  
 The blood samples were prepared according to standard protocols (see e.g. (de Witte et 
al., 2014)). Samples were centrifuged at 4800 rpm for 10 minutes to remove clotted cells and 
other debris. The plasma was then transferred into Geiner Bio-One Reaction Tubes (1.5 ml, PP, 
graduate, attached cap) and stored at – 80°C. 
8Plasma proteins were reduced with 10 mM dithiothreitol (DTT) for 30 min at 60 °C and 
then alkylated with 10mM iodoacetamide (IAA) for 30 min at room temperature in the dark. 
Tryptic digestion was performed using porcine trypsin (Sequencing Grade Modified, Promega, 
Winconsin) for 17 hours at 37 °C (Levin, Schwarz, Wang, Leweke, & Bahn, 2007). Samples 
were then spiked with a mixture of heavy isotope-labeled peptide standards and analyzed by 
nano Liquid chromatography- Multiple Reaction Monitoring Mass Spectrometry (nano LC–
MRM-MS). 
Mass spectrometry based protein quantification  
Tryptic digested proteins were quantified using Waters Xevo Triple quadrupole coupled to a 
nanoAcquity UPLC system (Waters Corporation, UK) and operated in the multiple reaction 
monitoring (MRM) mode as described previously (Wesseling, Gottschalk, & Bahn, 2014). The 
LC buffer system was as follows: mobile phase A, 0.1% formic acid and mobile phase B, 0.1% 
formic acid in acetonitrile. The peptides were separated and eluted at a flow rate of 300 nL/min 
using a 48-minute gradient of 97/3% (A/B) to 60/40% in 30 minutes; 60/40% to 15/85% in 2 
minutes; 5 minutes at 15/85%; and returning to the initial condition in 1 minute. The trapping 
and analytical columns were C18 (180 µmx20mm, 5-µm particle size) and C18 BEH nano-
column (75 µmx200mm, 1.7-mm particle size), respectively. 
 Forty-two plasma proteins were quantified using Psynova Human Blood Panel-42 
(Psynova Neurotech Ltd. Cambridge, UK)(Alsaif et al., 2012; Enaw & Smith, 2013; Schwarz 
et al., 2012; Schwarz et al., 2010a)(see Table 2). This selection was based on current findings 
in Schizophrenia and Bipolar disorder regarding the relevance of plasma proteins for etiological 
models of the diseases (see e.g., (Alsaif et al., 2012; Enaw et al., 2013; Schwarz et al., 2012; 
Schwarz et al., 2010b)).  
-----------------------------------------------Insert Table 2 about here------------------------------------- 
9 Briefly, unique peptides and fragment ions for each targeted proteins were selected as 
described previously (Wesseling et al., 2014). The peptides were then quantified along with 
spiked stable-isotope-labeled internal standards of the same sequence. Each sample was 
analysed in triplicate. 
Assessment of cognitive and clinical data 
Before conducting the MRI measurements, all participants were screened regarding their 
clinical symptomatology by an independent clinical expert. Furthermore, all participants 
underwent a psychometric assessment by an investigator of the study.  
Prior to clinical ratings, all participants completed the German version of the “Spot-the-
Word-Test” (MWT-B) to measure crystallised intelligence (Mehrfachwahl-Wortschatz-Test) 
(Lehrl, 2005) and the Trail Making Test A (TMT A) for psychomotor speed as well as the TMT 
B for executive functioning (Reitan, Hom, & Wolfson, 1988) (see Table 1 for further details). 
 To guarantee homogeneity between patient groups, it was ensured that the duration of 
illness (at a minimum of five years), the onset of disease and years of drug treatment were 
comparable between SZ and BD patients (see Table 1 for further details). All the patients’ 
treatment regimens were stable during the month preceding testing. There were no medication-
free patients; also none of them had received benzodiazepine drugs in the precedent month. All 
SZ patients were treated with second generation antipsychotic medications (in some cases also 
with first generation antipsychotics) at time of assessment. BD patients’ medication was 
grouped into three categories: lithium (lithium, lithium + antidepressant), other mood stabilisers 
(other mood stabilisers, other mood stabilisers + antidepressant) and antipsychotics 
(neuroleptics, neuroleptics + antidepressant) (see Table 1). In order to compare different 
substances and doses, chlorpromazine equivalents concerning antipsychotics (see the formula 
by (Woods, 2003)), amitryptiline equivalents concerning antidepressant drugs (Ali, 1998), and 
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mg of lithium, valproic acid and lamotrigine were computed. Furthermore, a ‘medication load’ 
based on a method first introduced by Almeida (Almeida et al., 2009) was calculated. 
Depressive symptom severity was assessed using the Beck Depression Inventory (BDI 
II) (Hautzinger, Keller, & Kühner, 2006), a widely accepted scale in Germany for the 
assessment of acute depressive symptoms. BD patients had a mean of 10.21 (9.39) in the BDI 
II sum scores indicateing subclinical depressive symptoms in BD patients, whereas controls 
had a mean of 2.09 (7.76) points in BDI II. Mania symptoms in BD patients and controls were 
measured using the widely used Bech-Rafaelsen Mania Scale (BRMAS) (Bech, 1981). Both, 
BD patients and controls had non-clinical scores of the BRMAS (BD patients: M=2.10 (2.75), 
controls: M=1.45 (1.12). However, none of the patients or controls had a score >19 in the BDI 
II and a score >7 in the BRMAS, which would indicate a clinically relevant symptomatology 
during testing (see Table 1). 
In addition to that, SZ patients were also tested for potential acute symptoms using the 
Positive and Negative Syndrome Scale (PANSS) (Kay, Fiszbein, & Opler, 1987). The following 
mean PANSS scores were present in SZ patients: global scale: M=66.85 (8.34), positive 
symptoms: M=17.01 (5.34), negative symptoms: M=17.88 (5.87) and general symptomatology: 
M=33.01 (8.49).  
Anatomical measurement 
Within one week of the data assessment, each participant underwent a high-resolution T1-
weighted anatomical measurement (MDEFT sequence; (Deichmann, Schwarzbauer, & Turner, 
2004), 176 slices, 1x1x1 mm) using a Siemens Magnetom Allegra 3 Tesla MRI system 
(Siemens Medical Systems, Erlangen, Germany) at the Goethe University Brain Imaging 
Centre, Frankfurt, Germany. Participants were scanned under dimmed lights and instructed to 
lie still and look at a white fixation cross presented in the centre of the visual field. Participants 
did not engage in any overt speech during the scanning sequences. The anatomical MRI scans 
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of all participants were reviewed by a neuroradiologist who did not find any clinically relevant 
pathology. 
A voxel-based morphometry approach (VBM) was applied to preprocess and analyse 
the anatomical data, using the SPM8 running on MATLAB® version 7.7.0 (Statistical 
Parametric Mapping [Wellcome Department of Imaging Neuroscience, London, UK]). All 
images were checked for artefacts, structural abnormalities and pathologies by two independent 
raters. Next, customized T1 templates and prior images of grey matter (GM), white matter 
(WM) and cerebro-spinal fluid (CSF) were created from all participants for use in the group 
analysis. We used modulated data and prior probability maps (voxel intensity) to guide 
segmentation. The segmentation included six different tissue types, light bias regularisation 
(0.001), 60 mm bias FWHM cut-off, warping regularisation of 4 mm, affine regularisation to 
the ICBM European brain template (linear registration) and a sampling distance of 3 mm. The 
quality of the segmentation was checked before further analysis. Finally, the images were 
smoothed with a Gaussian kernel of 8 x 8 x 8 mm (FWHM). Using this procedure, the intensity 
of each voxel was replaced by the weighted average of the surrounding voxels, blurring the 
segmented image. 
The pre-processed data were analysed using a region-of-interest (ROI) approach. 
Therefore, we took anatomical defined masks of the left and right hippocampus (see Figure 1 
for an illustration and detailed information of the masks) from the WFU PickAtlas toolbox in 
SPM8 (Maldjian, Laurienti, Burdette, & Kraft, 2003). The left hippocampus mask included 929 
volumes, the right hippocampus mask 949 volumes. The relative volume of each participant (t-
statistic for each voxel), using intracranial volume (ICV) as a nuisance variable, in the left and 
right hippocampus were extracted using the Marsbar-Tool® implemented in the SPM software. 
The resulting relative volume were extracted and imported into an SPSS 22.0 data sheet for 
further statistical testing. 
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-----------------------------------------Insert Figure 1 about here---------------------------------------- 
2.3 Statistical analysis 
 The statistical methods of this study were reviewed by the Department of Biostatistics, 
Faculty of Medicine, Goethe-University Frankfurt/Main, Germany. The strategy regarding 
statistical analyses included three steps.  
 First, for MRM analysis of the protein data, raw data of protein concentrations were 
processed using Skyline software and analysed using the MSstats® package (Choi et al., 2014) 
in R software (Core Team, 2014). This resulted in normalised log transformed relative 
intensities of protein concentrations, which were exported into SPSS® (SPSS, 2014) to test 
group comparisons. Group comparisons showed a statistical trend (p=0.09) regarding BMI 
scores due to lower scores in the control group in comparison with SZ and BD patients. BMI 
was a confounder [that is, BMI was associated with both protein levels and group (p < 0.05)] 
in some models. Consequently, to control for BMI, it was included in all statistical comparisons. 
Using the SPSS 22.0 software, linear mixed models (linear; random intercept) were performed 
on the protein levels, computing the following factors:  
1. Comparisons of protein levels between patients (SZ and BD patients) and controls 
2. Comparisons of protein levels between BD and SZ patients 
 Significance was based upon a threshold p-value defined using Bonferroni and an - 
level of 0.05. 
Second, bivariate correlation analyses using Pearson product-moment or Spearman 
Rank correlation coefficients (Bonferroni corrected) were performed to examine the 
relationships between the protein concentrations and other variables of interest (cognitive 
scores, hippocampus volume). However, only protein concentrations revealing significant 
contrasts during group comparisons of patients versus controls (first level) were included in 
these analyses. We also controlled for the potential influence of medication by performing 
bivariate correlation analyses (Spearman product-moment correlation, two-tailed) between the 
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protein scores and the medication doses, as well as the duration of medication in patients. 
Finally, we controlled for potential influence of clinical variables (BDI II, BRMAS, PANSS) 
on the protein concentrations, computing additional bivariate correlation analysis (Spearman 
rank correlation).  
3. Results 
3.1 Group comparisons of plasma protein concentration (MRM) 
Contrasts between patients (SZ and BD patients) and controls: Protein expressions in 
patients versus controls  
The following proteins showed different expressions in patients compared with controls: 
ANT3, ApoA1, ApoA2, ApoA4, ApoC1, ApoC2, ApoC3, ApoC4, ApoL1, C1QC, CFAB, 
CO3, F13B, FCN3, HEP2, HRG, KLKB1, PEDF, RET4 (all pBonf < 0.05). 
Contrasts between disease groups: Protein expression in BD versus SZ patients 
The following proteins showed significant dissimilarities between BD and SZ patients: A2AP, 
ANT3, ApoB, ApoD and ApoF (all pBonf <0.05). In comparison to SZ patients, BD patients 
displayed the tendency of having higher concentrations in the aforementioned proteins (see 
Table 3).   
-----------------------------------------Insert Table 3 about here---------------------------------------- 
-----------------------------------------Insert Figure 1 about here-------------------------------------- 
3.2 Correlation analyses 
In SZ patients, the negative association between ApoC2 scores and psychomotor speed 
(TMT A) and right HC volumes reached a significant level. In line with that, ApoC3 scores 
were inversely correlated with left and right hippocampus volumes, psychomotor speed and 
executive functioning. We also detected significant negative correlations between ApoC4 
14
scores and volumes of the right HC and psychomotor speed. ApoL1 scores were positively 
correlated with right hippocampus (all p £ 0.05; Bonferroni corrected; see Figure 3, Table 4 for 
details).  
In BD, higher crystallised intelligence scores were significantly associated with lower 
ApoC3 and ApoC4 levels, whereas bilateral HC volumes were inversely associated with ApoC3 
values and executive functioning was as well negatively correlated with ApoC3 levels (all p £
0.05). No significant relationship between the protein levels and any of the clinical scores across 
groups could be observed (all p > 0.05).  
 Computing bivariate correlation analyses independently of diagnosis groups (all 
participants included), lead to  results comparable to those found when doing the analyses for 
each group individually: significant correlations between APOC2, APOC3 and APOL1 and HC 
right volume; significant correlations between APOC2 and APOC4 with TMT A; and 
significant correlations between APOC3 and TMT B as well as HC left volume could be 
observed (please see Table 4 for further details).  
--------------------------------------------Insert Figure 3 about here---------------------------------- 
 The differences between the subject groups regarding gender, age and education did not 
reach statistical significance. Therefore, this variable was not included into the main analysis. 
However, additional correlation analyses were computed between the main results (ApoC 
values and age, gender as well as education) for each subject group individually. These analyses 
demonstrate no significant influence of age, gender and education to the protein values (p > 
0.05).  
 We controlled for potential association between affective symptom severity in BD 
patients and controls (BDI II, BRMAS) and cognitive performance (MWT-B, TMT A, TMT B) 
and could not found any significant relationship (p > 0.05). Accordingly, additional correlation 
analyses between cognitive performance (MWT-B, TMT A, TMT B) and psychotic symptoms 
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in SZ patients were conducted, in order to control for potential influence of symptom severity 
on the cognitive performance. However, no significant association between symptoms of 
psychosis as measured with the PANSS and cognitive performance in the cognitive domains 
measured with the TMT A, TMT B or MWT-B could be found (p > 0.05).  
3.6 Medication effects 
In SZ patients, high chlorpromazine equivalent scores were correlated with high ApoA4 
levels (p = 0.414, rho = 0.044). ApoA4 levels also correlated significantly with Almeida scores 
in BD patients (p = 0.453, rho = 0.045). None of the other protein concentrations revealed any 
significant association with medication scores. Duration of medication (in years) was not 
correlated with any of the protein levels (all p < 0.05).  
-------------------------------------Insert Table 4 about here-------------------------------------------- 
4. Discussion
Having outlined the results of the study at hand, the major findings will discussed in the 
following. First of all, a number of protein levels that differing between patients (SZ and BD) 
and controls could be observed. Secondly, A2AP, ApoB, ApoD, ApoF and ANT3 displayed 
differences across patient groups (SZ vs. BD). Moreover, apolipoprotein (ApoC) expressions 
were not only different between patients and controls, but were putatively related to cognitive 
impairments, as well as to hippocampus volumes. However, none of the protein level 
differences were related to clinical symptom severity. 
 Recent disease models of psychosis suggest that there are shared dysfunctional 
biological pathways contributing to the clinical signs of both disorders (Consortium et al., 2009; 
O'Donnell, Vohs, Hetrick, Carroll, & Shekhar, 2004; Sanchez-Morla et al., 2008; Smith, Barch, 
& Csernansky, 2009) but that there are also distinct symptoms and pathomechanisms. Changes 
in Apo concentrations have been demonstrated by several authors and have been linked to the 
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physiopathology of SZ (Lee, Kim, & Song, 2013La et al., 2007; Wu et al., 2013)(Sasaki et al., 
1985; Takahashi et al., 2008). The involvement of apolipoprotein dysfunction in the 
pathophysiology of SZ was also suggested by Martins-de-Souza and colleagues (Martins-de-
Souza et al., 2012). Accordingly, the results of the study at hand are consistent with those of 
Haenisch and colleagues (Haenisch et al., 2014) who conducted a multiplex analysis of plasma 
protein concentrations and described 26 dysregulated proteins in BD, including growth factors, 
hormones, lipid transport (e.g. APOA1) and inflammatory proteins. Our results are independent 
of acute symptomatology, although our study was neither powered nor specifically designed to 
assess such correlations since our patient samples showed relatively low severity scores for 
acute symptoms.  
 However, as a main outcome of the current study, direct associations between cognitive 
impairments, underlying structural abnormalities and altered protein expression in 
apolipoproteins could be observed in both disease groups. Primarily, we detected significant 
inverse correlations between concentrations of ApoC2, ApoC3, ApoC4 and psychomotor speed 
in SZ. As well, poorer executive functioning was inversely correlated with ApoC3 
concentration alterations in SZ and BD patients, both. This was accompanied by significant 
inverse correlations between ApoC3 and ApoC4 levels and crystallised intelligence in BD; i.e.
the poorer the cognitive performance, the higher the changes in Apo concentrations. Apo are 
involved in the metabolism and transport of lipids within the CNS as well as functioning in 
brain physiology. The involvement of altered Apo levels in decreased cognitive performance or 
cognitive decline has been proposed previously (Dassati et al., 2014; Elliott et al., 2010; Huang 
& Mahley, 2014; La et al., 2007), but has not yet been thoroughly investigated in SZ or BD. A 
study by Verbrugghe et al. (Verbrugghe et al., 2012) conducted an association analysis between 
disease outcome and cognitive performance in SZ. They described that ApoE, ApoER2, 
VLDLR, and DAB1 SNPs were significantly related to disease outcome, pre-morbid 
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intelligence and verbal memory. Thus, it was concluded that neurodevelopmental/synaptic 
plasticity genes are involved in cognitive deficits in SZ.  
Secondly, bilateral hippocampal (HC) volume was also inversely related to levels of 
ApoC3 in BD and SZ, i.e. the lower the volume, the higher the changes in Apo concentrations. 
Furthermore, ApoC2, Apo4 and ApoL1 levels were associated with right HC volumes in SZ 
patients. As the hippocampus plays a central role in cognitive functioning (Avery, Williams, 
Woolard, & Heckers, 2013) this finding may be of great importance. Taking into account that 
SZ patients display more cognitive deficits than BD patients, a stronger connection between 
imaging markers related to the HC and Apo concentrations may indicate a reflection of those 
deficits in SZ patients. Our results are in line with the report by Hwang and colleagues (Hwang 
et al., 2013), who detected that abnormal immune/inflammation response in the hippocampus 
was associated with abnormalities in the parvalbumin-containing neurons. The authors 
proposed that this altered hippocampus response might lead to the cognitive deficits underlying 
the pathophysiology of SZ. Consistenly, Vila-Rodriguez and co-workers (Vila-Rodriguez, 
Honer, Innis, Wellington, & Beasley, 2011) observed a significant negative association between 
ApoE concentration and GM volumes. Moreover, (Serra-Grabulosa et al., 2003) did not only 
state that ApoE and ApoC1 polymorphisms are genetic risk factors for dementia and cognitive 
impairment in the elderly, they also found that ApoC1 is associated with changes in 
hippocampal volumes in elderly people with cognitive impairments. Although those results 
were not corrected for sociodemographic differences, they hint towards a connection between 
ApoC1, neuronal changes in the area of the HC and cognitive deficits.  
Strength and limitations 
 Although in this study, it was carefully controlled for confounders, such as acute 
symptomatology or medication dosage, these variables might still influence the direction and 
intensity of protein changes. The relationship between metabolic problems, such as obesity, 
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diabetes and elevated lipids, and the expression of Apo has been frequently investigated in the 
general population (Padrao, Ferreira, Vitorino, & Amado, 2012; Ramachandran et al., 2012; 
Sadler et al., 2012). Due to antipsychotic medications in SZ and mood stabilisers in BD, those 
patients have an increased risk for metabolic disturbances and altered lipid metabolism 
(Gibbons, Thomas, Scarr, & Dean, 2010), ultimately contributing to an increased risk for 
cardiovascular disease (Meyer et al., 2008). Several authors observed an association between 
Apo concentrations in patients receiving psychiatric medication (e.g., phenothiazines, 
olanzapine, risperidone) (Dean et al., 2008; Sasaki et al., 1985; Smith, Segman, Golcer-Dubner, 
Pavlov, & Lerer, 2008; Song et al., 2014). Therefore, we controlled for potential effects of the 
duration of drug treatment, the dosage of the current treatment, as well as BMI values on the 
protein concentrations. No relationship between psychiatric medication use, BMI, and any of 
the protein concentrations except for ApoA4 concentration could be found (which was a 
parameter that did not differ significantly across groups). Nevertheless, in order to control for 
potential metabolic side effects, in the future a group of patients not taking any psychiatric 
medication might be helpful to detect potential impacts of medication on the findings.  
Another limitation of this current study could be seen in its relatively small size. 
However, this can be attributed to the very strict inclusion criteria; the severity of symptoms 
were comparable; ensuring that none of the patients had any history of drug addiction; and 
participant groups were carefully matched. Consequently, taking into account the inherent lack 
of reproducibility in proteomic studies (Song et al., 2014), the results need to be replicated in 
larger samples. Hence, further investigations regarding multiple protein concentrations in a 
single study may be necessary to detect potential links between clinical outcome or cognitive 
decline and the markers of interest.   
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Conclusion 
Regarding the discussion about shared or distinct pathophysiological pathways in BD 
and SZ (see (Kraepelin, 1896) and (Craddock & Owen, 2005)), we present evidence indicating 
that both disorders share predominant Apo alterations which are connected to psychomotor 
speed, executive functioning and crystallised intelligence, as well as to hippocampus volume. 
Therefore, this result indicates that Apo might be useful biomarkers for cognitive dysfunction 
in both disorders, consistent with the NIMH RDoC framework (Wang & Insel, 2010).  
Furthermore, the strong correlation of cognitive performance and volume in HC with 
Apo levels in SZ could be a reflection of the latter suffering from more severe deficits. 
Accordingly, based on the fact that none of the assessed clinical parameters were associated 
with serum levels of protein markers, it could be assumed that the protein levels are associated 
with cognitive deficits rather than with affective or psychotic symptoms in BD and SZ.  
Intriguingly, our results are consistent with recent genome-wide association studies 
revealing partial, but not complete, overlap of the genetic risk profiles for BD and SZ (Hall et 
al., 2014). Our results suggest that the detection of molecular patterns in association with 
cognitive performance. Its underlying brain morphology is of great importance in the 
understanding of the pathological mechanisms of SZ and BD and may lead to novel biological 
diagnostic tools (Haenisch et al., 2014). Although the presented findings are of great interest to 
psychiatric research, further studies are needed to explore and explain these graded changes in 
SZ and BD in order to define which parameters show graded changes and which do not. The 
changes in the Apo plasma level before and after treatment with antipsychotics should also be 
further investigated. Finally, as present findings in other disorders, e.g., Alzheimer’s disease, 
and the fact that both, SZ and BD display overlapping  results regarding apolipoprotein 
dysfunctions, it could suggested/ assumed that these changes are not specific for psychosis but 
instead rather characterise a phenotype across psychiatric disorders related to cognitive 
functioning.  
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Table 1: Sociodemographic, clinical and cognitive variables across groups.  
Mean and SD (in brackets). BDI II = Beck Depression Inventory, PANSS = Positive and 
Negative Syndrome Scale, f = female, m = male.  SZ = schizophrenia, BD = bipolar patients, 
CON = controls. * = significant differences on  level of p £ 0.05; ** = significant differences 
on  level of p £ 0.01; *** = significant differences on an  level of p £ 0.001. 
 SZ BD CON Statistics 
p
Number 29 25 93 - 
Gender (f / m) 8 / 21 6 / 19 39 / 44 Kruskal-wallis: 
p=0.156 
Age (years) 
M (SD)
37.16 (10.96) 37.79 (10.40) 33.59 (11.18) p = 0.117 
Education 
(years) 
 M (SD)
15.09 (3.19) 15.19 (2.37) 16.14 (1.96) p=0.06 
Handedness all right handed 
Duration of 
illness (years) M 
(SD) 
11.81 (7.79) 8.860 (5.47) - p = 0.06 
Onset of disease 
(years) M (SD) 
25.75 (5.34) 29.60 (10.98) - p = 0.07 
BMI 
(kg/m2) M (SD) 
28.33 (6.37) 28.12 (3.23) 24.09 (15.33) p = 0.09 
Medication
(years) M (SD) 
  6.88 (4.56) 7.23 (2.34) - p=0.37 
Medication 
equivalents 
M (SD) 
Chlorpromazine 
equivalents 
(mg/day):  
580.92 (230.12) 
Medication 
load: 2.44 (1.19) 
Amitriptyline-
equivalent 
(mg/day): 
123.12 (80.23) 
Valproic acid 
(mg/day):  
1215.14 
(801.53) 
Medication 
categories
please see Table S2 please see Table 
S2 
- - 
BDI II 10.85 (3.13) 10.21 (9.39) 2.09 (7.76) p = 0.0009*** 
BRMAS - 2.10 (2.75) 1.45 (1.12) p=0.70  
PANSS PANSS pos: 17.01 
(5.34),  
PANSS neg: 17.88 
(5.87)  
26
PANSS gen: 33.01 
(8.49),  
PANSS sum: 66.85 
(8.34) 
Medication 
categories 
quetiapin (n=25) 
quetiapin + 
antidepressant 
(n=1) 
risperidon + 
antidepressant 
(n=1) 
amisulprid + 
antidepressant 
(n=1) 
apipriprazol + 
antidepressant 
(n=1) 
quetiapin + 
haloperidol (n = 5) 
apipriprazol + 
haloperidol (n = 4) 
lithium (n = 13) 
lithium + 
bupropion (n=1) 
lithium + 
valdoxan (n=1) 
lamotrigin (n=3) 
valproin acid 
(n=1) 
lamotrigin + 
antidepressant 
(n = 1) 
quetiapin (n=4) 
quetiapin + 
antidepressant 
(n=1) 
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Table 2: Complete list of the assessed serum markers according to the immunoassay platforms 
Human ImmunoMAP® and Human DiscoveryMAP® of the MyriadRBM®. Abbreviations = 
Abbv. Sources: * = uniprot.org, ** = rbm.myriad, a = (Gagliardi, Ho, & Torpy, 2010), b = 
(Kashuba, Bailey, Allsup, & Cawkwell, 2013). 
Number Serum protein Abbv. Function 
 MRM-assessment 
1 Alpha 1-antitrypsin A1AT acute-phase-protein* 
2 Alpha 2-antiplasmin/ plasmin 
inhibitor 
A2AP thrombogene* 
3 Alpha 2-macroglobulin A2MG thrombogene* 
4 Adenine nucleotide translocase 
3 
ANT3 apoptosis* 
5 Apolipoprotein A1 APOA1 lipid transport* 
6 Apolipoprotein A2 APOA2 lipid transport* 
7 Apolipoprotein A4 APOA4 lipid transport* 
8 Apolipoprotein B APOB lipid transport* 
9 Apolipoprotein C1 APOC1 lipid transport* 
10 Apolipoprotein C2 APOC2 lipid transport* 
11 Apolipoprotein C3 APOC3 lipid transport* 
12 Apolipoprotein C4 APOC4 lipid transport* 
13 Apolipoprotein D APOD lipid transport* 
14 Apolipoprotein E APOE lipid transport* 
15 Apolipoprotein F APOF lipid transport* 
16 Apolipoprotein H APOH lipid transport* 
17 Apolipoprotein L1 APOL1 lipid transport* 
18 Apolipoprotein M APOM lipid transport* 
19 Apolipoprotein O APOO lipid transport* 
20 Transcortin CBG regulation of cortisol activitya
21 Ceruloplasmin CERU acute-phase-protein* 
22 Clusterin CLUS apoptose, complement 
induced celllyse * 
23 Complement component 3 CO3 acute-phase-protein, 
complement system * 
24 Complement C4A CO4A complement system* 
25 Complement component C9 CO9 complement-system* 
26 Complement C1q  C1QC complement system* 
27 Complement factor B CFAB complement system* 
28 Ficolin-3 FCN3 complement system* 
29 Coagulation factor XIII B/ 
clotting factor 
F13B koagulation, fibrin stabiliser* 
30 HSP70 Escort Protein 2 HEP2 apoptose* 
31 Haptoglobin   HPT acute-phase-protein* 
32 Haptoglobin related protein HPTR acute-phase-protein* 
28
33 Histidine-rich glycoprotein HRG immunological* 
34 C1-inhibitor/ C1 esterase 
inhibitor 
IC1 complement system* 
35 Immunoglobulin heavy constant 
µ
IGHM immunological* 
36 Plasma-Kallikrein KLKB1 Koagulation, Kallikrein-
Kinin systemb
37 Matrix metalloproteinase 9 MMP9 immunological * 
38 Pigment epithelium-derived 
factor 
PEDF immunological * 
39 Phosphatidylinositol-Glycan-
specific phospholipase D 
PHLD lipid metabolism * 
40 Plasminogen PLMN immunological, acute-phase-
protein, fibrinlyse* 
41 Retinol-binding protein 4 RET4 sugar metabolism** 
42 Transferrin TRFE immunological** 
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Table 3: Mean and Standard Deviations across groups and Statistical group comparisons. The 
data are normalised log transformed relative intensities of protein concentrations. We used 
linear mixed models (linear; random intercept) of the protein data adjusted for BMI scores. SZ 
= schizophrenia, BD=bipolar patients, CON =controls, PAT=patients. Mean = mean, SD = 
standard deviation. * = significant differences on  level of p £ 0.05; ** = significant differences 
on  level of p £ 0.01; *** = significant differences on an  level of p £ 0.001. 
Scores SZ 
M (SD)
BD          
M (SD)
PAT 
M (SD) 
CON 
M (SD)
Statistical Group 
Comparison patients 
vs. controls
Statistical 
Group 
Comparisons 
BD / SZ p
A2AP 17.495 
(0.819)
18.013 
(0.447)
17.717 
(0.496) 
17.571 
(0.709)
F=0.582, p=0.563 0.009** 
ANT3 17.425 
(1.112)
18.196 
(0.524)
17.791 
(1.033) 
17.460 
(0.993)
F=4.143, p=0.024* 0.011* 
APOA1 21.963 
(0.231)
23.015 
(0.132)
22.511 
(1.504) 
22.430 
(0.123)
F=3.684, p=0.034* 0.253 
APOA2 17.963 
(1.769)
18.858 
(0.307)
18.476 
(1.350) 
18.186 
(1.125)
F=3.655, p=0.035* 0.247 
APOA4 20.097 
(0.123)
20.411 
(0.l43)
20.307 
(0.698) 
20.123 
(1.023)
F=3.887, p=0.029* 0.155 
APOB 15.997 
(0.264)
16.119 
(0.379)
16.054 
(1.114) 
16.207 
(0.396)
F=0.368, p=0.694 0.005** 
APOC1 19.367 
(1.039)
20.096 
(0.326)
19.470 
(0.958) 
19.130 
(0.966)
F=6.127, p=0.005** 0.278 
APOC2 21.938 
(0.759) 
21.882 
(0.653)
21.896 
(0.715) 
21.501 
(0.572)
F=6.338, p=0.004** 0.207 
APOC3 22.441 
(0.965)
22.704 
(0.653)
22.518 
(0.809) 
22.209 
(0.526)
F=6.902, p=0.003** 0.261 
APOC4 18.982 
(0.404)
18.834 
(0.543)
18.905 
(0.416) 
18.819 
(0.327)
F=4.828, p=0.014* 0.172 
APOD 19.597 
(0.181)
19.850 
(0.261)
19.683 
(0.669) 
19.657 
(0.272)
F=0.728, p=0.489 0.050* 
APOE 19.428 
(0.202)
19.465 
(0.291)
19.435 
(0.889) 
19.312 
(0.303)
F=2.705, p=0.080 0.077 
APOF 17.990 
(0.164)
18.129 
(0.137)
17.950 
(0.644) 
17.992 
(0.236)
F=0.470, p=0.629 0.015* 
APOL1 18.079 
(0.669)
18.199 
(0.251)
18.111 
(0.572) 
19.009 
(0.377)
F=5.269, p=0.010* 0.214 
C1QC 16.343 
(0.342)
16.224 
(0.125)
18.711 
(0.794) 
16.376 
(0.125)
F=3.845, p=0.030* 0.167 
CFAB 19.582 
(0.519)
19.609 
(0.225)
19.599 
(0.503) 
19.401 
(0.473)
F=6.580, p=0.004** 0.278 
CO3 22.790 
(0.686)
22.673 
(0.185)
22.703 
(0.537) 
22.652 
(0.302)
F=4.931, p=0.012* 0.221 
F13B 17.222 
(0.123)
17.177 
(0.423)
17.190 
(0.517) 
17.327 
(0.195)
F=3.938, p=0.028* 0.175 
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FCN3 19.581 
(0.776)
19.634 
(0.418)
19.602 
(0.616) 
19.548 
(0.463)
F=5.055, p=0.011* 0.187 
HEP2 18.857 
(0.927)
19.290 
(0.718)
19.090 
(0.800) 
18.863 
(0.594)
F=6.109, p=0.005** 0.330 
HRG 19.324 
(0.596)
19.332 
(0.362)
19.309 
(0.501) 
19.454 
(0.343)
F=4.594, p=0.016* 0.172 
KLKB1 18.495 
(0.461)
18.252 
(0.203)
18.310 
(0.388) 
18.483 
(0.264)
F=4.057, p=0.025* 0.266 
MMP9 17.994 
(0.187)
17.668 
(0.123)
17.787 
(0.496) 
17.583 
(0.128)
F=3.079, p=0.058 0.160 
PEDF 19.294 
(0.866)
19.453 
(0.370)
19.401 
(0.662) 
19.277 
(0.608)
F=4.853, p=0.013* 0.209 
RET4 19.917 
(0.234)
20.001 
(0.154)
19.989 
(0.587) 
19.856 
(0.768)
F=3.922, p=0.028* 0.148 
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Table 4: Significant correlations (two-tailed; Bonferroni corrected). Spearman rank correlation 
= rho, Pearson Product Moment correlation = r, SZ = schizophrenia patients, BD = bipolar 
patients, CON = controls. TMT A = Trail Making Test A, MWT-B = Mehrfachwahl-Wortschatz-
Test (Spot-the-Word-Test), HC= hippocampus volume. 
 Significant correlations  
Protein BD SZ Total 
APOC2  TMT A: r=-0.45, p=0.002                             
HC right: r=-0.54, 
p=0.006 
TMT A: r=-0.35, p=0.001 
HC right: r=-0.25, p=0.02 
APOC3 MWT-B: r= -0.56, 
p=0.009
HC left: r=-0.62, p= 
0.003                           
HC right: r=-0.65, p= 
0.002                          
TMT B: r=-0.49, 
p=0.008 
HC left: r=-0.45, p=0.003                          
HC right: r= -0.41, 
p=0.004                                       
TMT A: r=-0.52, p = 0.01
TMT B: r=-0.43, p = 0.01 
HC left: r=-0.39, p=0.03 
HC right: r=-0.26, p=0.01 
TMT B: r=-0.48, p=0.01 
APOC4 MWT-B: r=-0.56, p= 
0.009 
TMT A: r=-0.49, p = 0.01             
HC right: r =-0.51, p= 
0.01  
TMT A: r=-0.37, p=0.001 
APOL1  HC right: r=0.42, 
p=0.004                                         
HC right: r=0.25, p=0.02 
APOA4 Almeida: p = 0.453, rho
= 0.045* 
Chlorpromazine: p = 
0.414, rho = 0.044* 
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Figure 1: Illustration of the masks used for the VBM analysis. The masks were extracted 
using the WFU PickAtlas toolbox in SPM8 (Maldjian et al., 2003) and the Marsbar-Tool. 
Hippocampus mask left: -28, -15, -25 (929 volumes); hippocampus mask right: 21, -21, -24 
(949 volumes).  
Hippocampus mask for VBM analysis                 
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Figure 2: Illustration of the statistical group comparisons, using linear mixed models (linear; 
random intercept) of the protein data adjusted for BMI scores. We show those results which 
deemed significant during group comparisons. A. shows all significant contrasts between 
patient groups (BD and SZ) and controls, B. shows all significant contrasts between BD and 
SZ patients. Abbreviations: SZ = schizophrenia, BD = bipolar patients, CON = controls. Mean 
= mean, SD = standard deviation.  
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Figure 3: Illustration of the main findings of the study and the functional relevance of the 
protein alterations. 
